The companies expect to report top-line results from this pivotal trial by July 2008 and submit a new drug application for Acurox tablets to the FDA before the end of 2008.
Eric Carter, chief science officer of King, said: “We expect that Acurox tablets will be the first approved immediate-release opioid analgesic designed to resist or deter common methods of prescription drug abuse.”